top of page
Executive Spotlights

AbbVie to Pay OSE Immunotherapeutics an Upfront Payment of $48M and Offer Potential Additional Milestone Payments of up to $665M

North Chicago, IL, and Nantes, France, February 28, 2024 (PRNewswire)  -- AbbVie and OSE Immunotherapeutics announced a partnership to advance OSE-230, a monoclonal antibody targeting chronic and severe inflammation.  Currently in the pre-clinical development phase, the collaboration helps AbbVie expand their immunology portfolio.

Read full article here.

Recent Posts

See All

Radiant Vision Systems Appoints new CEO

Redmond, WA, July 1, 2024 (Radiant) -- Radiant Vision Systems has appointed Stone Jiang as their new CEO, succeeding Doug Kreysar who is retiring. Jiang, previously the Executive Vice President and

Orion and Merck Secure $1.63B Agreement

Rahway, NJ, July 1, 2024 (Business Wire) -- Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, and Orion Corporation ("Orion") have agreed to convert their co-development and co-commercial


Life Science Headlines
bottom of page